Indiana University, Bloomington, IN
Daniel Wolin is a Senior Director in the Surveys and Observational Studies group at RTI-HS where he leads and supports a variety of projects, including observational studies (qualitative and quantitative), postauthorization safety studies, clinical trials, safety, and various training initiatives. He has experience in a number of clinical areas including dermatology, autoimmune conditions, pain/inflammation, ophthalmology, oncology. Prior to joining RTI-HS, Mr. Wolin spent 10 years in the pharmaceutical industry in drug safety and regulatory affairs. He has worked in a variety of therapy areas, including ophthalmology, pain/inflammation, dermatology, oncology, cardiovascular, central nervous system, metabolic and cell therapy (autologous). Mr. Wolin has led numerous Food and Drug Administration meetings (pre-IND, end of phase 2, and labeling discussions) and has been involved with early development projects through approval and postmarketing programs. While at Pfizer, Mr. Wolin acted as a global regulatory lead and was responsible for coordinating and progressing global regulatory projects in the United States, Japan, and the European Union.